BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 7832859)

  • 1. Predicting complete cytogenetic response in chronic myelogenous leukemia patients treated with recombinant interferon alpha.
    Mahon FX; Montastruc M; Faberes C; Reiffers J
    Blood; 1994 Nov; 84(10):3592-4. PubMed ID: 7832859
    [No Abstract]   [Full Text] [Related]  

  • 2. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service.
    Kantarjian HM; Smith TL; O'Brien S; Beran M; Pierce S; Talpaz M
    Ann Intern Med; 1995 Feb; 122(4):254-61. PubMed ID: 7825760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon alpha-2c therapy of patients with chronic myelogenous leukemia: long-term results of a multicenter phase-II study. Austrian Biological Response Modifier (BRM) Study Group.
    Thaler J; Gastl G; Fluckinger T; Niederwieser D; Huber H; Seewann H; Sill H; Lang A; Falk M; Duba C; Utermann G; Kühr T; Aulitzky W; Huber C
    Ann Hematol; 1996 Jun; 72(6):349-55. PubMed ID: 8767103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytogenetics and molecular analysis in chronic myelogenous leukemia patients treated by interferon and chemotherapy.
    Guilhot F; Ahmad M; Mahon FX; Dreyfus B; Brizard A; Huret JL; Kitzis A; Tanzer J
    Nouv Rev Fr Hematol (1978); 1990; 32(5):287-8. PubMed ID: 2099398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon alfa-2c in chronic myelogenous leukemia (CML): hematologic, cytogenetic and molecular-genetic response of patients with chronic phase CML previously resistant to therapy with interferon gamma.
    Herrmann F; Jonas D; Helfrich SG; Lindemann A; Schleiermacher E; Mertelsmann R
    Blut; 1990 Oct; 61(4):226-31. PubMed ID: 2121299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined therapy interferon and chemotherapy in chronic myelogenous leukemia.
    Guilhot F; Dreyfus B; Desmarest MC; Giraud C; Huret JL; Brizard A; Tanzer J
    Nouv Rev Fr Hematol (1978); 1989; 31(2):171-3. PubMed ID: 2771633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients.
    Talpaz M; Kantarjian H; Kurzrock R; Trujillo JM; Gutterman JU
    Ann Intern Med; 1991 Apr; 114(7):532-8. PubMed ID: 2001086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Interferon alfa-2b treatment of adult patients during early chronic phase of Ph1-positive chronic myeloid leukemia (initial report on a cooperative study, protocol CML-MIG-97)].
    Khoroshko ND; Turkina AG; Zakharova AV; Kobzev IuN; Domracheva EV; Tikhonova LIu; Semenova EA; Zhuravlev VS; Sokolova MA; Kuznetsov SV
    Ter Arkh; 1999; 71(7):42-7. PubMed ID: 10481867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polyclonal hematopoiesis in interferon-induced cytogenetic remissions of chronic myelogenous leukemia.
    Claxton D; Deisseroth A; Talpaz M; Reading C; Kantarjian H; Trujillo J; Stass S; Gooch G; Spitzer G
    Blood; 1992 Feb; 79(4):997-1002. PubMed ID: 1371081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-interferon antibodies in alpha interferon treated patients with chronic myeloid leukaemia.
    Aitchison R; Allen P; Schey S; Newland AC
    Br J Haematol; 1991 Jul; 78(3):465-7. PubMed ID: 1873235
    [No Abstract]   [Full Text] [Related]  

  • 11. Quantitative determination of the hybrid Bcr-Abl RNA in patients with chronic myelogenous leukaemia under interferon therapy.
    Malinge MC; Mahon FX; Delfau MH; Daheron L; Kitzis A; Guilhot F; Tanzer J; Grandchamp B
    Br J Haematol; 1992 Dec; 82(4):701-7. PubMed ID: 1482657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histopathological changes in bone marrow biopsies from patients with chronic myeloid leukaemia after treatment with recombinant alpha-interferon.
    Facchetti F; Tironi A; Marocolo D; Capucci A; Ruggeri G; Bellotti D; Rossi G
    Histopathology; 1997 Jul; 31(1):3-11. PubMed ID: 9253618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A case of chronic myeloid leukemia with cytogenetic remission and disappearance of Ph1 positive cells due to interferon-alpha administration].
    Yoshida M; Fujiwara Y; Yoshinaga H; Maeda T; Mori Y; Nonaka K; Senoo K; Atsui F
    Nihon Naika Gakkai Zasshi; 1991 May; 80(5):766-7. PubMed ID: 1875114
    [No Abstract]   [Full Text] [Related]  

  • 14. Response to recombinant interferon alpha in patients with chronic myelogenous leukemia in a single center: results and analysis of predictive factors.
    Montastruc M; Mahon FX; Fabères C; Marit G; Bilhou-Nabera C; Cony-Makhoul P; Puntous M; Pigneux A; Boiron JM; Bernard P
    Leukemia; 1995 Dec; 9(12):1997-2002. PubMed ID: 8609708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic myelocytic leukemia patients achieving complete cytogenetic conversion under interferon alpha therapy: minimal residual disease follow-up.
    Bilhou-Nabéra C; Marit G; Gharbi MJ; Salzes S; Mahon FX; Broustet A; Reiffers J; Bernard P
    Leukemia; 1995 Dec; 9(12):2067-70. PubMed ID: 8609718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583.
    Ozer H; George SL; Schiffer CA; Rao K; Rao PN; Wurster-Hill DH; Arthur DD; Powell B; Gottlieb A; Peterson BA; Rai K; Testa JR; LeBeau M; Tantravahi R; Bloomfield CD
    Blood; 1993 Nov; 82(10):2975-84. PubMed ID: 8219189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-alpha plus low-dose cytosine arabinoside in advanced phase chronic myelogenous leukaemia patients.
    Ferrajoli A; Liberati AM; Caricchi P; Donti E; Morra E; Lazzarino M; Betti AR; Bernasconi P; Saglio G
    Eur J Haematol; 1995 Sep; 55(3):184-8. PubMed ID: 7672091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of alpha-interferons in chronic myelogenous leukaemia.
    Talpaz M
    Br J Clin Pract Suppl; 1988 Mar; 62():13-5. PubMed ID: 3145008
    [No Abstract]   [Full Text] [Related]  

  • 19. Southern technique and cytogenetics are complementary and must be used together in the evaluation of Ph1, M-BCR positive chronic myeloid leukemia (CML) patients treated with alpha interferon (IFN-alpha).
    Steegmann JL; Requena MJ; Casado LF; Pico M; Peñarrubia MJ; Ferro MT; Resino M; Fernandez-Rañada JM
    Am J Hematol; 1996 Nov; 53(3):169-74. PubMed ID: 8895687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantification of BCR-ABL transcripts in CML patients in cytogenetic remission after interferon-alpha-based therapy.
    Martinelli G; Testoni N; Amabile M; Bonifazi F; De Vivo A; Farabegoli P; Terragna C; Montefusco V; Ottaviani E; Saglio G; Russo D; Baccarani M; Rosti G; Tura S
    Bone Marrow Transplant; 2000 Apr; 25(7):729-36. PubMed ID: 10745258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.